	US 7,541,353 B2
	Compounds for the treatment of hepatitis C
Robert G. Gentles, Wallingford, Conn. (US); Xiaofan Zheng, Cheshire, Conn. (US); Min Ding, Glastonbury, Conn. (US); Yong Tu, Cheshire, Conn. (US); Ying Han, Cheshire, Conn. (US); Piyasena Hewawasam, Middletown, Conn. (US); John F. Kadow, Wallingford, Conn. (US); John A. Bender, Middletown, Conn. (US); Kap-Sun Yeung, Madison, Conn. (US); Katharine A. Grant-Young, Madison, Conn. (US); and Thomas W. Hudyma, Durham, Conn. (US)
Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US)
Filed on Mar. 11, 2008, as Appl. No. 12/45,874.
Claims priority of provisional application 60/989473, filed on Nov. 21, 2007.
Claims priority of provisional application 60/894885, filed on Mar. 14, 2007.
Prior Publication US 2008/0226591 A1, Sep. 18, 2008
Int. Cl. A61P 31/00 (2006.01); A61K 31/55 (2006.01); C07D 223/14 (2006.01)

U.S. Cl. 514—214.01 [540/576]

12 Claims

1. A compound of formula I

R¹is CO₂R⁵or CONR⁶R⁷;

R²is

R³is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, or alkoxy;

R⁴is cycloalkyl;

R⁵is hydrogen or alkyl;

R⁶is hydrogen, alkyl, alkylSO₂, cycloalkylSO₂, haloalkylSO₂, (R¹⁰)(R¹¹)NSO₂, or (R¹²)SO₂;

R⁷is hydrogen or alkyl;

R⁸is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, or benzyl;

R⁹is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, or benzyl;

or NR⁸R⁹taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl;

R¹⁰is hydrogen or alkyl;

R¹¹is hydrogen or alkyl;

R¹²is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-(alkyl)piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl;

R¹³is hydrogen or alkyl; and

R¹⁴is hydrogen, alkyl, cycloalkyl, or haloalkyl;

or a pharmaceutically acceptable salt thereof.